Online inquiry

IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1814MR)

This product GTTS-WQ1814MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CFD gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317335.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1675
UniProt ID P00746
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1814MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10681MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ1262MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-414
GTTS-WQ10615MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ7378MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ2923MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ69MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ10301MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ11121MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MDX-060
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW